Replies to post #58111 on Anavex Life Sciences Corp (AVXL)

[JB3729]

Prana's drug was a good candidate for failure. It was not reversing the effects of Alzheimer's like A2-73, just possibly slowing progression.

Macfarlane's enthusiasm during the Prana trial was directed at one patient. Currently, his enthusiasm is for the entire A2-73 trial.

Macfarlane said that the drug seems to have slowed the progression of the disease by about 30 percent in patients with mild Alzheimer’s compared to placebo.

https://www.equities.com/news/prana-biotechnology-pran-continues-upward-on-alzheimer-s-disease-drug-news